17.8 kg body-weight loss with bimagrumab + semaglutide vs 14.2 kg with semaglutide · 48 weeks
BELIEVE · Nature Medicine · The combination used bimagrumab 30 mg/kg plus semaglutide 2.4 mg; the comparison arm used semaglutide 2.4 mg plus bimagrumab placebo. · Least-squares means, treatment-regimen estimand: all randomized participants regardless of adherence or discontinuation; placebo-based imputation for missing values. Uncertainty below is standard error, not CI.
17.8 kg body-weight loss with bimagrumab + semaglutide vs 14.2 kg with semaglutide · 48 weeks
The combination used bimagrumab 30 mg/kg plus semaglutide 2.4 mg; the comparison arm used semaglutide 2.4 mg plus bimagrumab placebo.
Adults with BMI ≥30, or ≥27 with an obesity-associated complication; diabetes excluded.
Least-squares means, treatment-regimen estimand: all randomized participants regardless of adherence or discontinuation; placebo-based imputation for missing values. Uncertainty below is standard error, not CI.
Safety context
Muscle spasms, acne and diarrhea were more frequent with bimagrumab. LDL cholesterol increased with the combination.
Through week 48 · 57 participants were randomized per selected arm; 55 combination recipients and 56 semaglutide recipients received at least one study-treatment dose and entered the safety analysis.
Limitations: Phase 2; nominal comparisons without multiplicity adjustment. Lean mass is not direct muscle measurement. Most grip-strength comparisons were nonsignificant. Muscle spasms, diarrhea, acne and laboratory/lipid changes matter; the 72-week extension is open-label and post hoc. A later withdrawal abstract reports partial regain after treatment stopped; see the safety notes for its separate follow-up population and limitations.
Status in this atlas: Current approval status is not summarized in this therapy record. A trial phase or a brand name does not establish approval for this use.
Crystal structure of the antigen-binding Fab portion of bimagrumab.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Crystal structure of the antigen-binding Fab portion of bimagrumab.
Shown: Fab fragment only; not the full bimagrumab IgG
X-ray diffraction, 1.78 Å. This source-rendered ribbon contains the heavy- and light-chain Fab domains. The Fc region and the second Fab arm of the full therapeutic antibody are absent; unresolved atoms are not drawn.
A next milestone is not summarized for this therapy. This does not mean development has ended.
Development history1 selected milestones
Bimagrumab · compound history across indications
This timeline includes selected body-composition publications and any separately sourced regulatory updates. It is not a complete development history; earlier clinical work and other indications may be missing.
Publication
BELIEVE publication
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
